Mitoxantrone,cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial |
| |
| Authors: | Bruce Dana Steve Dahlberg Bertram Schnitzer Carl R Kjeldsberg Stephen E Jones Juan Carden Richard Mundis Bill Tranum |
| |
| Institution: | (1) Oregon Health Sciences University, USA;(2) Southwest Oncology Group Statistical Center, Seattle, USA;(3) University of Michigan Medical Center, USA;(4) University of Utah Medical Center, USA;(5) Arizona Cancer Center, USA;(6) St. Louis CCOP, USA;(7) Midwest CCOP, USA;(8) Arkansas CCOP, USA |
| |
| Abstract: | Summary A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All patients had relapsed after only one prior chemotherapy regimen (CHOP — 56%; mBACOD — 28%). There were three complete and eight partial responses (overall response rate — 34%) among 32 eligible patients. The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 patients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia.We conclude that mitoxantrone-cisplatin-MGBG has modest activity as salvage treatment in malignant lymphoma patients, but produces severe toxicity.
Address for offprints: Southwest Oncology Group (SWOG-8369), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA. |
| |
| Keywords: | non-Hodgkin's lymphoma chemotherapy cisplatinum mitoxantrone methyl glyoxal bis-guanyl hydrazone |
| 本文献已被 SpringerLink 等数据库收录！ |
|
